drugset / Trial / NCT05002816
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.
Timeline
- Start
- 2022-02-21
- Primary completion
- 2026-01-22
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belantamab mafodotin | Monoclonal antibody | 1.4 mg/kg | Intravenous |
| Subject | Belantamab mafodotin | Monoclonal antibody | 1.9 mg/kg | Intravenous |
| Subject | Elotuzumab | Monoclonal antibody | 20 mg/kg | Intravenous |